Pulmatrix Adds Patents Covering iSPERSE Technology
Pulmatrix has gained two more U.S. patents covering the company’s iSPERSE inhaled dry powder technology, the Lexington, Mass., devicemaker said Thursday. These new issuances bring Pulmatrix’s global patents for the technology up to 36, covering the iSPERSE powder until at least 2030.
The technology consists of a combination of salts and amino acids engineered into small, dense particles, containing properties with the potential to allow for new treatments of lung disease or facilitate better delivery of pharmaceuticals to the lungs.
iSPERSE particles are easily dispersed, reduce systemic exposure and potential side effects, and flow rate independent which means they can be delivered reliably regardless of patient lung function, the company claims.
The devicemaker says the technology could solve significant limitations of available inhaled technologies, including nebulizers, metered dose inhalers, and conventional lactose blend dry powder inhalers. — Jason Scott